Oncological Benefits of Pressured Intraperitoneal Aerosol Chemotherapy (PIPAC) in Patients With T3-4 Gastric Cancer Cyt-
Status:
Recruiting
Trial end date:
2029-01-10
Target enrollment:
Participant gender:
Summary
Stomach cancer is recognized as the third leading cause of death of cancer patients
worldwide. Despite the radical treatment carried out, the progression of gastric cancer
occurs in 30-40% of patients. The most common type of tumor progression of this localization
is peritoneal carcinomatosis. When peritoneal carcinomatosis occurs, the median survival of
patients does not exceed 3 months, the overall survival is no more than 6 months.
Unfortunately, when peritoneal carcinomatosis occurs, palliative chemotherapy remains the
only treatment option. The modern strategy for the prevention and treatment of peritoneal
carcinomatosis is based on the concept of regional chemotherapy. The main methods of regional
chemotherapy are hyperthermic intraperitoneal chemotherapy (HIPEC) and Pressured
Intraperitoneal Aerosol Chemotherapy (PIPAC). PIPAC is a new technology for delivering
chemotherapy drugs to tumor nodes on the surface of the peritoneum and allows the cytostatic
to be evenly distributed over the abdominal cavity, increasing the depth of its penetration
into tumor nodes due to the properties of aerosol and gradients of intra-abdominal and
interstitial pressure. The method has a number of advantages over the HIPEC method: a large
penetration depth of drugs, low trauma, the possibility of repeated use. We offer PIPAC for
patients with locally advanced gastric cancer and a high risk of developing peritoneal
carcinomatosis in an adjuvant mode in addition to standard treatment to prevent the
development of carcinomatosis.